SCHEMBL3096345

SCHEMBL3096345

Cc1ccc2c(c1Cl)NC(=O)C2(O)C1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 6/20 0.43
BRD2 P25440 1/20 0.33
BRD3 Q15059 1/20 0.33
BRDT Q58F21 1/20 0.33
ADAMTS5 Q9UNA0 2/20 0.33
POLB P06746 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
HTT P42858 2/20 0.32
APOBEC3A P31941 1/20 0.32
HSD17B10 Q99714 1/20 0.32
APOBEC3G Q9HC16 1/20 0.32
ALDH1A1 P00352 2/20 0.32
PDE7A Q13946 1/20 0.32
NPC1 O15118 1/20 0.30
TSHR P16473 1/20 0.30
RAB9A P51151 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
EPHX2 P34913 1/20 0.30
IDO1 P14902 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3092409 1.00 BRD4 (0.43) BRD4BRD2BRD3BRDTADAMTS5
SCHEMBL3080911 1.00 BRD4 (0.43) BRD4BRD2BRD3BRDTADAMTS5
SCHEMBL3093549 0.99 BRD4 (0.42) BRD4BRD2BRD3BRDTADAMTS5
SCHEMBL3089769 0.86 BRD4 (0.45) BRD4BRD2BRD3BRDTPOLB
SCHEMBL3082149 0.86 BRD4 (0.45) BRD4BRD2BRD3BRDTPOLB
SCHEMBL3088871 0.84 BRD4 (0.43) BRD4BRD2BRD3BRDTADAMTS5
SCHEMBL3096358 0.84 BRD4 (0.43) BRD4BRD2BRD3BRDTPOLB
SCHEMBL3082410 0.84 BRD4 (0.43) BRD4BRD2BRD3BRDTPOLB
SCHEMBL3096095 0.84 BRD4 (0.43) BRD4BRD2BRD3BRDTADAMTS5
SCHEMBL3086066 0.84 BRD4 (0.43) BRD4BRD2BRD3BRDTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024175114-A1 BORON CONTAINING COMPOUNDS AND THERAPEUTIC USES THEREOF Shanghai Yuyao Biotech Ltd. (CN) 2024-08-29 WO disclosed
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TOPOTARGET A/S (DK) 2010-09-09 US disclosed
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TOPOTARGET A/S (DK) 2010-09-09 US disclosed
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TOPOTARGET A/S (DK) 2010-09-09 US disclosed
EP-2139856-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE-COMPOUNDS Topotarget A/S (DK) 2010-01-06 EP disclosed
WO-2008129075-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE-COMPOUNDS TOPOTARGET A/S (DK) 2008-10-30 WO disclosed
WO-2008129075-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE-COMPOUNDS TOPOTARGET A/S (DK) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TPH2, TPH1, HTR2C BRD4 616/4885BRD2 1442/4885BRD3 1098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.